These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10350122)

  • 21. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
    Lee JH; Chang JH
    Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyfra 21-1 and TPA as markers in malignant mesothelioma.
    Bonfrer JM; Schouwink JH; Korse CM; Baas P
    Anticancer Res; 1997; 17(4B):2971-3. PubMed ID: 9329578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
    Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
    Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
    Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A
    Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue polypeptide antigen and carcinoembryonic antigen as tumor markers in lung cancer.
    Lee YC; Yang PC; Kuo SH; Luh KT
    J Formos Med Assoc; 1991 Jul; 90(7):631-6. PubMed ID: 1681012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer.
    Kashiwabara K; Nakamura H; Kiguchi T; Yagyu H; Kishi K; Wei BR; Yoneyama K; Matsuoka K
    Clin Chim Acta; 1997 Oct; 266(2):149-55. PubMed ID: 9437543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma.
    Kao CH; Hsieh JF; Ho YJ; Ding HJ
    Lung; 1999; 177(5):333-7. PubMed ID: 10467024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma.
    Yoshimasu T; Miyoshi S; Maebeya S; Suzuma T; Bessho T; Hirai I; Tanino H; Arimoto J; Naito Y
    Cancer; 1997 Apr; 79(8):1533-40. PubMed ID: 9118035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
    Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
    Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
    J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
    Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
    Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y
    Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer.
    Tomita M; Shimizu T; Ayabe T; Yonei A; Onitsuka T
    Anticancer Res; 2010 Jul; 30(7):3099-102. PubMed ID: 20683062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of biological tumor markers CEA, Cyfra-21, NSE, TU M2-PK in diagnosis and treatment of lung cancer].
    Lazarev SM; Massard Zh; Reshetov AV; Nikolaev GV; Volgin GN; Osipov EV; Lomteva EIu; Nokhrin AV; Kakysheva OE
    Vestn Khir Im I I Grek; 2010; 169(1):39-43. PubMed ID: 20387605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.
    Muley T; Fetz TH; Dienemann H; Hoffmann H; Herth FJ; Meister M; Ebert W
    Lung Cancer; 2008 Jun; 60(3):408-15. PubMed ID: 18083270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.